UCI Merage MBA Deadlines 2025-2026
The UCI Merage MBA deadlines for the 2025-2026 admissions season are below.
UCI Merage is conducting its MBA application process in four rounds. Round 3 is the final deadline for international applicants.
| Rounds | Application Deadline | Decision Notification |
|---|---|---|
| Round 1 | October 15, 2025 | December 12, 2025 |
| Round 2 | January 15, 2026 | March 2026 |
| Round 3 | March 1, 2026 | April 2026 |
| Round 4 | May 1, 2026 | June 2026 |
Required Materials
Applications are processed in the order in which they are received. Applicants must submit the online application form, GMAT or GRE scores (waiver available), copies of academic transcripts from a bachelor’s degree from an accredited college or university, essay question responses, a resume, and two professional recommendations. The application fee is $150.
When Does UCI Merage Issue Invitations to Interview?
Interviews are offered by invitation only (via email) after an applicant has submitted all of the application components. The timing of an interview invitation has no bearing on admission. Interviews are conducted in-person or via Zoom.
MBA Applywire
Chemical Engineering Bachelors and Masters (3.44 and 3.88 respectively)
Currently mentoring entry level engineers as well.
Worried about transition from a more engineering field to consulting and how the masters impacts admission odds
Background:
24F, Indian
GPA - 7.5 from a Tier 1 Indian college
Participated in CBSE Swimming nationals, and won medals in relay
Took part in badminton clusters
Was part of the prefectorial body in which we welcomed delegates from all around the world
Took part in a NASA program wherein we visited the Johnson Space Centre in Houston
College:
Not good GPA but can defend it
Part of college badminton team and won many laureates
Got bronze in an inter-collegiate tournament as the women’s badminton team captain. And created history as this wasn’t achieved before by any woman’s badminton team
Was the sportswoman of the year for my college
Was part of the incubation center management team of the college. Was part of the strategic relations team (where we almost got Steve Wozniak to deliver a speech) and was the event management team lead
Work Experience:
3yrs Software eng/ quant experience in a top investment bank (front office and back office Eng roles)
Got a promotion
Lead a 2months intern project
What are my chances for the above colleges for a MBA and can I expect any scholarship?
Should I retake the test? Planning to apply in R1
Two-time founder (marketing agency during undergrad, then a fintech post-graduation), ex-Kearney consulting, currently on the founding team of a boutique financial consulting firm. Based in Pakistan, 29. Forbes 30 Under 30 honoree. Undergrad from LUMS (top business school in Pakistan) with a 2.91 GPA, which I know is my main weakness.
Targeting HBS, Stanford, and MIT Sloan for R1. I'm aware these are reaches given my GPA. GRE is in progress, currently retaking to push into the 315 to 320 range with a strong quant score to offset the academic profile.
Post-MBA goal is to scale into senior operating or founder roles in fintech and financial services, building on my consulting and startup background.
GMAT/GRE waiver, realistically what are my chances? I have 4 major exercises and 1 deployment. The reason for the waiver is time constraints as I am currently deployed.
I'm a dentist from India exploring international MBA programs and would appreciate some advice from people who have either gone through a similar transition or have experience with MBA admissions and outcomes.
My long-term goal is to move into the healthcare/healthtech ecosystem, potentially in areas such as healthcare consulting, product management, healthcare strategy, or healthtech startups. I am particularly interested in leveraging my clinical background rather than moving into a completely unrelated field.
I'm currently evaluating MBA programs in Europe and Asia (Singapore, Japan, HongKong)
For context, I have a GMAT Focus score of 575 with 4 years of work ex within the clinical and corporate side of the healthcare sector